Athersys, Inc.
Biotech Specialty Pharma
3201 Carnegie Avenue
Cleveland, OH 44115-2634 USA
phone: 216-431-9900
fax: 216-361-9495
Symbol Private
Founded 0
Employees
www.athersys.com
Research Sector Biotech Specialty Pharma
Summary Description
Therapeutic products for treatment of significant and life-threatening diseases.
Management
Gil Van Bokkelen, Ph.D., Chairman and CEO; John Harrington, Ph.D., Executive Vice President and Chief Scientific Officer; William (B.J.) Lehmann, J.D., President and Chief Operating Officer; Kurt Brunden, Ph.D., Senior Vice President of Drug Discovery; Robert Deans, Ph.D., Vice President, Regenerative Medicine; Laura Campbell, Vice President of Finance
Keywords
obesity, cognitive disorder, asthma, cardiovascular disease, stroke, immune system disorder, diabete

Comment | Printable Version | Mar. 19, 2007
If you work for Athersys, Inc. and want to update this profile, click here


Description
Athersys is focused on the development and commercialization of therapeutic products that treat significant and life-threatening diseases.
Products / Services
The Company has multiple synthetic pharmaceutical programs targeting receptor systems important in obesity, cognition and other CNS disorders, and asthma. The most advanced of these programs is in the obesity area, which has focused on developing multiple classes of compounds against a portfolio of three distinct drug targets. The Company selected a clinical candidate in the obesity area, ATHX-105, and intends to file an IND in early 2006.


2008-11-21-671